Advertisement
Advertisement
CLDX
Celldex Therapeutics, Inc
41.71
USDSponsored
+0.15
+0.36%
Aug 07, 15:59 UTC -4
Closed
After-Market
41.77
+0.05
+0.13%
CLDX Earnings Reports
Positive Surprise Ratio
CLDX beat 29 of 42 last estimates.
69%
Next Report
Date of Next Report
Nov 09, 2026
Estimate for Q3 26 (Revenue/ EPS)
$1.07M
/-$1.10
Implied change from Q2 26 (Revenue/ EPS)
+5226.64%
/+17.02%
Implied change from Q3 25 (Revenue/ EPS)
--
/+8.91%
Celldex Therapeutics, Inc earnings per share and revenue
On Aug 06, 2026, CLDX reported earnings of -0.94 USD per share (EPS) for Q2 26, beating the estimate of -1.07 USD, resulting in a 12.79% surprise. Revenue reached 20.00 thousand, compared to an expected 973.53 thousand, with a -97.95% difference. The market reacted with a +0.36% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 10 analysts forecast an EPS of -1.10 USD, with revenue projected to reach 1.07 million USD, implying an increase of 17.02% EPS, and increase of 5226.64% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Cytokinetics Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.67
Actual
-$1.50
Surprise
+10.35%
ANI Pharmaceuticals, Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
$2.09
Actual
$2.21
Surprise
+5.69%
Zymeworks Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.46
Actual
-$0.62
Surprise
-32.31%
Intellia Therapeutics, Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.81
Actual
-$0.80
Surprise
+1.86%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.43
Surprise
-9.58%
CytomX Therapeutics, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-13.78%
Verastem, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.44
Actual
-$0.35
Surprise
+20.69%
ALX Oncology Holdings Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.14
Actual
-$0.13
Surprise
+11.08%
Arcturus Therapeutics Holdings Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.01
Actual
-$0.84
Surprise
+17.53%
Entera Bio Ltd. Ordinary Shares
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.14
Surprise
-71.57%
FAQ
What were Celldex Therapeutics, Inc's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Celldex Therapeutics, Inc reported EPS of -$0.94, beating estimates by 12.79%, and revenue of $20.00K, -97.95% below expectations.
How did the market react to Celldex Therapeutics, Inc's Q2 2026 earnings?
The stock price moved up 0.36%, changed from $41.56 before the earnings release to $41.71 the day after.
When is Celldex Therapeutics, Inc expected to report next?
The next earning report is scheduled for Nov 09, 2026.
What are the forecasts for Celldex Therapeutics, Inc's next earnings report?
Based on 10
analysts, Celldex Therapeutics, Inc is expected to report EPS of -$1.10 and revenue of $1.07M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement